To the claims:

Please amend Claims 16-18, 38-40, and 53-55.

The currently pending and amended claims are below. Please amend the claims following, wherein the deleted matter is shown by strikethrough and the added matter is shown by underlining.

- 1. (Original) A method of stabilizing a neural cell comprising:
 - (a) providing a pluripotent mammalian cell;
 - (b) culturing the pluripotent mammalian cell to produce a neural cell; and
 - (c) contacting the neural cell with a MEDII conditioned medium for greater than 2 passages to thereby stabilize the neural cell.
- 2. (Original) The method of Claim 1, whereby step (b) occurs in the presence of a feeder cell layer.
- 3. (Original) The method of Claim 1 wherein step (b) comprises the use of a medium comprising a compound selected from the group consisting of KSR, GMEM, HES medium, or any combination thereof.
- 4. (Original) The method of Claim 1, further comprising an additional step of contacting the cells with a differentiating medium prior to contact with the MEDII conditioned medium.
- 5. (Original) The method of Claim 4, wherein the differentiating medium is essentially serum free.
- 6. (Original) The method of Claim 4 where the differentiating medium further comprises a base salt solution.
- 7. (Original) The method of Claim 6 where the base salt solution selected from the group consisting of DMEM, GMEM or any combination thereof.
- 8. (Original) The method of Claim 4 wherein the differentiating medium further comprises supplements selected from the group consisting of N2, FGF2, or any combination thereof.

- 9. (Original) The method of Claim 1, wherein the MEDII conditioned medium is essentially serum free.
- 10. (Original) The method of Claim 1, wherein the mammalian pluripotent cell is selected from the group consisting of an embryonic stem cell, an ICM/epiblast cell, a primitive ectoderm cell, a primordial germ cell, and a teratocarcinoma cell.
- 11. (Original) The method of Claim 10, wherein the mammalian pluripotent cell is a human embryonic stem cell.
- 12. (Original) The method of Claim 2, wherein the feeder cell layer comprises a stromal cell.
- 13. (Original) The method of Claim 12, wherein the stromal cell is a murine stromal cell.
- 14. (Original) The method of Claim 13, wherein the stromal cell is a PA6 cell.
- 15. (Original) The method of Claim 12, wherein the stromal cell is human stromal cell.
- 16. (Currently amended) The method of any one of Claim[[s]] 1[[-15]], wherein the MEDII conditioned medium is a HepG2 conditioned medium.
- 17. (Currently amended) The method of any one of Claim[[s]] 1[[-15]], wherein the MEDII conditioned medium comprises a biologically active component selected from the group consisting of:
 - (a) a large molecular weight extracellular matrix protein;
 - (b) a low molecular weight component comprising proline;
 - (c) a biologically active fragment of any of the proteins or components described in a) or b);
 - (d) an analog of any of the proteins or components described in a) or b);
 - (e) a neural inducing factor; and
 - (f) any combination thereof.
- 18. (Currently amended) The method of any one of Claim[[s]] 1[[-15]], wherein the MEDII conditioned medium comprises a large molecular weight extracellular matrix protein.

- 19. (Original) The method of Claim 1 wherein the neural cell is plated prior to contact with the MEDII conditioned medium.
- 20. (Original) The method of Claim 19, wherein the neural cell is plated with a feeder cell layer prior to contact with the MEDII conditioned medium.
- 21. (Original) The method of Claim 19, wherein the neural cell is plated on a substrate prior to contact with the MEDII conditioned medium.
- 22. (Original) The method of Claim 1, further comprising the step of isolating the neural cell after step (b) prior to contacting the neural cell with the MEDII conditioned medium.
- 23. (Original) The method of Claim 22, wherein isolating the neural cell comprises manually selecting the neural cell.
- 24. (Original) The method of Claim 1, further comprising the subsequent step of differentiating the stabilized neural cell to produce a differentiated neural cell.
- 25. (Original) The method of Claim 24, wherein the differentiated neural cell is TH positive, and expresses DAT and V-MAT.
- 26. (Original) The method of Claim 25, wherein a population of differentiated neural cells is produced, and at least 50% of the population of differentiated neural cells is TH positive.
- 27. (Original) The method of Claim 24, wherein the differentiated neural cell expresses glutamate decarboxylase.
- 28. (Original) The method of Claim 24, wherein the differentiated neural cell expresses GFAP.
- 29. (Original) The method of any one of Claims 1-28, wherein the neural cell is a neural progenitor cell.
- 30. (Original) A method of stabilizing a neural cell comprising:
 - (a) providing a mammalian neural cell; and
 - (b) contacting the neural cell with a MEDII conditioned medium for greater than 2 passages to thereby stabilize the neural cell.

- 31. (Original) The method of Claim 30, wherein the neural cell is plated prior to contact with the MEDII conditioned medium.
- 32. (Original) The method of Claim 31, wherein the neural cell is plated with a feeder cell layer prior to contact with the MEDII conditioned medium.
- 33. (Original) The method of Claim 32, wherein the feeder cell layer comprises a stromal cell.
- 34. (Original) The method of Claim 33, wherein the stromal cell is human stromal cell.
- 35. (Original) The method of Claim 31, wherein the neural cell is plated on a substrate prior to contact with the MEDII conditioned medium.
- 36. (Original) The method of Claim 30, wherein the neural cell is a neural progenitor cell.
- 37. (Original) The method of Claim 30, wherein the mammalian neural cell is a human neural cell.
- 38. (Currently amended) The method of any one of Claim[[s]] 30[[-37]], wherein the MEDII conditioned medium is a HepG2 conditioned medium.
- 39. (Currently amended) The method of any one of Claim[[s]] 30[[-37]], wherein the MEDII conditioned medium is essentially serum free.
- 40. (Currently amended) The method of any one of Claim[[s]] 30[[-37]], wherein the MEDII conditioned medium comprises at least a biologically active component selected from the group consisting of:
 - (a) a large molecular weight extracellular matrix protein;
 - (b) a low molecular weight component comprising proline;
 - (c) a biologically active fragment of any of the proteins or components described in a) or b);
 - (d) an analog of any of the proteins or components described in a) or b);
 - (e) a neural inducing factor; and
 - (f) any combination thereof.
- 41. (Original) The method of Claim 30, further comprising the additional step of differentiating the stabilized neural cell to produce a differentiated neural cell.

- 42. (Original) The method of Claim 41, wherein the differentiated neural cell is TH positive, and expresses DAT and V-MAT.
- 43. (Original) The method of Claim 42, wherein a population of differentiated neural cells is produced, and at least 50% of the population of differentiated neural cells are TH positive.
- 44. (Original) The method of Claim 41, wherein the differentiated neural cell expresses glutamate decarboxylase.
- 45. (Original) The method of Claim 41, wherein the differentiated neural cell expresses GFAP.
- 46. (Original) A composition comprising an isolated neural cell, wherein the cell expresses nestin, wherein the cell has been stabilized by contact with MEDII conditioned medium for greater than 2 passages, and wherein the cell can differentiate into more than one type of further differentiated neural cell.
- 47. (Original) The composition of Claim 46, wherein the cell has been stabilized by contact with MEDII conditioned medium for greater than 5 passages.
- 48. (Original) The composition of Claim 46, wherein the cell has been stabilized by contact with MEDII conditioned medium for greater than 10 passages.
- 49. (Original) The composition of Claim 46, wherein the cell has been stabilized by contact with MEDII conditioned medium for greater than 20 passages.
- 50. (Original) The composition of Claim 46, wherein the cell has been stabilized by contact with MEDII conditioned medium for greater than 30 passages.
- 51. (Original) The composition of Claim 46, wherein the cell has been stabilized by contact with MEDII conditioned medium for more than one year.
- 52. (Original) The composition of Claim 46, wherein the neural cell is a neural progenitor cell.
- 53. (Currently amended) The composition of any one of Claim[[s]] 46[[-52]], wherein the MEDII conditioned medium is a HepG2 conditioned medium.

National phase of PCT/US2003/040762 Preliminary Amendment

Filed: June 17, 2005

Page 8 of 9

- 54. (Currently amended) The composition of any one of Claim[[s]] 46[[-52]], wherein the MEDII conditioned medium is essentially serum free.
- 55. (Currently amended) The composition of any one of Claim[[s]] 46[[-52]], wherein the MEDII conditioned medium comprises at least a biologically active component selected from the group consisting of:
 - (a) a large molecular weight extracellular matrix protein;
 - (b) a low molecular weight component comprising proline;
 - (c) a biologically active fragment of any of the proteins or components described in a) or b);
 - (d) an analog of any of the proteins or components described in a) or b);
 - (e) a neural inducing factor; and
 - (f) any combination thereof.